Literature DB >> 18037620

Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption.

Hamish Dobbie1, Robert J Unwin, Nuno J R Faria, David G Shirley.   

Abstract

BACKGROUND: Matrix extracellular phosphoglycoprotein (MEPE), first isolated from tumour-derived tissue from a patient with oncogenic hypophosphataemia, is a putative phosphatonin that has received much less attention than fibroblast growth factor-23. To date, its effect on renal tubular phosphate reabsorption remains undefined.
METHODS: A renal clearance study was performed in anaesthetized rats infused intravenously with a range of doses of MEPE.
RESULTS: MEPE had no effect on glomerular filtration rate (inulin clearance) but caused rapid, dose-dependent increases in absolute and fractional phosphate excretion, wholly attributable to reduced phosphate reabsorption. At a maximal dose, MEPE increased fractional phosphate excretion more than 2-fold, whereas no change was observed in time controls.
CONCLUSION: The results lend support to the hypothesis that MEPE contributes to the phosphaturia of oncogenic hypophosphataemia and of hypophosphataemic rickets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037620     DOI: 10.1093/ndt/gfm535

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  22 in total

Review 1.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

2.  Human stanniocalcin-1 or -2 expressed in mice reduces bone size and severely inhibits cranial intramembranous bone growth.

Authors:  Jennifer Johnston; Yudith Ramos-Valdes; Lee-Anne Stanton; Sadia Ladhani; Frank Beier; Gabriel E Dimattia
Journal:  Transgenic Res       Date:  2010-02-20       Impact factor: 2.788

Review 3.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

4.  ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.

Authors:  Valentin David; Aline Martin; Anne-Marie Hedge; Marc K Drezner; Peter S N Rowe
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-22

Review 5.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

6.  Phosphatonins: new hormones involved in numerous inherited bone disorders.

Authors:  Laura Masi
Journal:  Clin Cases Miner Bone Metab       Date:  2011-09

7.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

8.  The phosphate transporter NaPi-IIa determines the rapid renal adaptation to dietary phosphate intake in mouse irrespective of persistently high FGF23 levels.

Authors:  Soline Bourgeois; Paola Capuano; Gerti Stange; Reto Mühlemann; Heini Murer; Jürg Biber; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2013-05-26       Impact factor: 3.657

9.  Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.

Authors:  William H Hoffman; Alka Jain; Harold Chen; Neal S Fedarko
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

10.  Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  Bone       Date:  2015-06-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.